- https://doi.org/10.1136/jim-2016-000120.73
ID: 95: IL-33/ST2 TRIGGERING OF IL-9–SECRETING T CELLS: FROM PROTEOMICS TO THERAPEUTICS
Translate Article 
Take Notes As one of the most validated immunotherapies to date, allogeneic hematopoietic cell transplantation (allo-HCT) is a potentially curative option for high-risk hematological malignancies, particularly acute myeloid leukemia (AML). The immunotherapeutic...
- Abstract
- 10.1016/s1525-0016(16)33317-2
- May 1, 2016
- Molecular Therapy
508. IL-33/ST2 Triggering of IL-9-Secreting T Cells: From Proteomics to Therapeutics
- Abstract
3 - 10.1182/blood.v126.23.231.231
- Dec 3, 2015
- Blood
IL-33/ST2 Triggering of IL-9-Secreting T Cells Alters the Balance of Fatal Immunity and Tumor Immunity
- Research Article
- 29
- 10.1016/j.bbmt.2010.10.031
- Nov 1, 2010
- Biology of Blood and Marrow Transplantation
Minimal Residual Disease following Allogeneic Hematopoietic Stem Cell Transplantation
- Research Article
- 22
- 10.1046/j.1365-2141.1998.00830.x
- Aug 1, 1998
- British Journal of Haematology
The role of repeat transplantation of haemopoietic stem cells and adoptive immunotherapy in treatment of leukaemia relapsing following allogeneic transplantation.
- Abstract
- 10
- 10.1182/blood.v124.21.3939.3939
- Dec 6, 2014
- Blood
Transferred Donor-Derived Virus Specific CD8+ T Cells That Have Been Transduced to Express a WT1-Specific T Cell Receptor Can Persist and Provide Anti-Leukemic Activity in AML Patients Post-Transplant
- Abstract
- 3
- 10.1182/blood-2019-123139
- Nov 13, 2019
- Blood
β2- Adrenergic Signaling Regulates Graft Versus Host Disease after Allogenic Transplantation While Preserving Graft Versus Leukemia Effect
- Research Article
- 128
- 10.1016/j.bbmt.2010.08.001
- Aug 8, 2010
- Biology of Blood and Marrow Transplantation
NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation
- Abstract
- 10.1182/blood.v118.21.4527.4527
- Nov 18, 2011
- Blood
Allogeneic Stem Cell Transplantation (allo-SCT) for Acute Myeloid Leukemia (AML): Low Incidence of Relapse and Graft Versus Host Disease (GVHD) in Patients (pts) Transplanted without Active Leukemia Using in-Vivo T-Cell Depletion with Rabbit Anti-Thymocyte Globulin (r-ATG)
- Abstract
- 10.1182/blood.v120.21.350.350
- Nov 16, 2012
- Blood
Transferred Donor-Derived WT1-Specific CD8+ T-Cell Clones After Hematopoietic Cell Transplantation Mediate Antileukemic Activity and Can Establish Persistent Responses without Toxicity to Normal Tissues in High-Risk Leukemia Patients
- Research Article
- 10.1182/blood-2025-4083
- Nov 3, 2025
- Blood
Galectin-3 in host murine models lessens the severity of graft-versus-host disease by preserving intestinal stem cells irrespective of gut microbiota composition
- Research Article
- 97
- 10.1016/j.bbmt.2010.05.007
- May 26, 2010
- Biology of Blood and Marrow Transplantation
Conditioning with Treosulfan and Fludarabine followed by Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies
- Abstract
- 10.1182/blood-2020-141120
- Nov 5, 2020
- Blood
Population Distribution of GvL and GvH Minor Histocompatibility Antigens
- Research Article
- 10.1097/01.cot.0000512060.75241.ec
- Jan 10, 2017
- Oncology Times
Cellular Immunotherapies for Leukemia Patients
- Abstract
- 10.1182/blood-2024-201237
- Nov 5, 2024
- Blood
Ropeginterferon Alfa-2b Induces Apoptosis and Differentiation of Leukemia Stem Cells and Separates GVL Effects from Gvhd after Allogeneic Hematopoietic Cell Transplantation
- Abstract
- 10.1182/blood.v130.suppl_1.3280.3280
- Jun 25, 2021
- Blood
Phase I Study of Bortezomib Combined with Lenalidomide for Relapsed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Following Hematopoietic Cell Transplantation
- Ask R Discovery
- Chat PDF
AI summaries and top papers from 250M+ research sources.
